KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Charles River Laboratories International (CRL) over the last 17 years, with Q3 2025 value amounting to $7.5 billion.

  • Charles River Laboratories International's Liabilities and Shareholders Equity fell 612.24% to $7.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $30.2 billion, marking a year-over-year decrease of 654.75%. This contributed to the annual value of $7.5 billion for FY2024, which is 813.49% down from last year.
  • Per Charles River Laboratories International's latest filing, its Liabilities and Shareholders Equity stood at $7.5 billion for Q3 2025, which was down 612.24% from $7.6 billion recorded in Q2 2025.
  • In the past 5 years, Charles River Laboratories International's Liabilities and Shareholders Equity registered a high of $8.2 billion during Q4 2023, and its lowest value of $5.8 billion during Q1 2021.
  • Its 5-year average for Liabilities and Shareholders Equity is $7.5 billion, with a median of $7.6 billion in 2025.
  • Per our database at Business Quant, Charles River Laboratories International's Liabilities and Shareholders Equity soared by 3539.19% in 2021 and then tumbled by 813.49% in 2024.
  • Quarter analysis of 5 years shows Charles River Laboratories International's Liabilities and Shareholders Equity stood at $7.0 billion in 2021, then increased by 8.24% to $7.6 billion in 2022, then increased by 7.79% to $8.2 billion in 2023, then dropped by 8.13% to $7.5 billion in 2024, then fell by 0.19% to $7.5 billion in 2025.
  • Its last three reported values are $7.5 billion in Q3 2025, $7.6 billion for Q2 2025, and $7.6 billion during Q1 2025.